

## New England Biolabs Certificate of Analysis

**Product Name:** BssHII  
**Catalog #:** R0199S/L  
**Concentration:** 5,000 units/ml  
**Unit Definition:** One unit is defined as the amount of enzyme required to digest 1 µg Lambda DNA in 1 hour at 50°C in a total reaction volume of 50 µl.  
**Lot #:** 0281306  
**Assay Date:** 06/2013  
**Expiration Date:** 06/2015  
**Storage Temp:** -20 °C  
**Storage Conditions:** 300 mM NaCl, 10 mM Tris-HCl (pH 7.4), 1 mM DTT, 0.1 mM EDTA, 50% Glycerol, 500 µg/ml BSA  
**Specification Version:** PS-R0199S/L v1.0  
**Effective Date:** 20 Dec 2013

Assay Name/Specification (minimum release criteria)	Lot #0281306
<b>Blue-White Screening (Terminal Integrity)</b> - A sample of LITMUS28i vector linearized with a 10-fold excess of BssHII, religated and transformed into an <i>E. coli</i> strain expressing the LacZ beta fragment gene results in <1.0% white colonies.	<b>Pass</b>
<b>Exonuclease Activity (Radioactivity Release)</b> - A 50 µl reaction in CutSmart™ Buffer containing 1 µg of a mixture of single and double-stranded [ <sup>3</sup> H] <i>E. coli</i> DNA and a minimum of 50 units of BssHII incubated for 4 hours at 50°C releases <0.1% of the total radioactivity.	<b>Pass</b>
<b>Ligation and Recutting (Terminal Integrity)</b> - After a 20-fold over-digestion of Lambda DNA with BssHII, >95% of the DNA fragments can be ligated with T4 DNA ligase in 16 hours at 16°C. Of these ligated fragments, >95% can be recut with BssHII.	<b>Pass</b>
<b>Non-Specific DNase Activity (16 Hour)</b> - A 50 µl reaction in CutSmart™ Buffer containing 1 µg of Lambda DNA and a minimum of 50 Units of BssHII incubated for 16 hours at 50°C results in a DNA pattern free of detectable nuclease degradation as determined by agarose gel electrophoresis.	<b>Pass</b>

\* The BSA in this product has been granted an EDQM "Certificate of Suitability" from the European Directorate for the Quality of Medicines (# R1-CEP-2003-204-Rev00) and has been granted a USDA Certificate for Export of Bovine Blood Plasma/Serum for Manufacture into Pharmaceutical Products.



Authorized by  
Derek Robinson  
20 Dec 2013



Inspected by  
David Hough  
20 Dec 2013

